Fmr LLC Sells 3,062,525 Shares of Hookipa Pharma Inc (NASDAQ:HOOK)

Fmr LLC trimmed its position in shares of Hookipa Pharma Inc (NASDAQ:HOOK) by 90.0% during the 3rd quarter, HoldingsChannel reports. The fund owned 341,476 shares of the company’s stock after selling 3,062,525 shares during the quarter. Fmr LLC’s holdings in Hookipa Pharma were worth $1,468,000 as of its most recent filing with the Securities & Exchange Commission.

Separately, Renaissance Technologies LLC increased its stake in Hookipa Pharma by 38.4% during the second quarter. Renaissance Technologies LLC now owns 302,246 shares of the company’s stock valued at $179,000 after acquiring an additional 83,800 shares during the period. Institutional investors own 63.88% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on HOOK shares. JMP Securities decreased their price objective on Hookipa Pharma from $24.00 to $7.00 and set a “market outperform” rating on the stock in a report on Thursday, November 21st. Royal Bank of Canada decreased their price objective on Hookipa Pharma from $50.00 to $48.00 and set an “outperform” rating on the stock in a report on Friday, November 15th.

Hookipa Pharma Trading Down 0.5 %

NASDAQ HOOK opened at $2.13 on Monday. The stock’s 50 day moving average is $3.24 and its two-hundred day moving average is $4.87. The company has a market capitalization of $25.68 million, a price-to-earnings ratio of -0.57 and a beta of 0.71. Hookipa Pharma Inc has a 1-year low of $1.88 and a 1-year high of $11.30.

Hookipa Pharma Company Profile

HOOKIPA Pharma Inc, a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors.